ASPIVIX is redefining the standard of care in gynecology through its mission to make routine procedures less painful, more dignified, and more respectful for women. Its flagship innovation, Carevix, is a suction-based cervical stabilizer that replaces the tenaculum, a sharp, traumatic instrument invented over a century ago. Carevix is FDA-cleared and CE-marked, with clinical data from IU Health and Columbia University supporting its efficacy. Over 1,300 patients have benefited from the device, with a remarkable 94% patient satisfaction. Carevix significantly reduces pain and bleeding during intrauterine procedures such as IUD insertions, endometrial biopsies, and fertility assessments. ASPIVIX has also led national conversations around the urgent need for innovation in gynecology. Its viral awareness campaign – reaching over 3.3 million views on TikTok – has sparked powerful dialogue among patients, providers and policymakers. It was also named one of TIME Magazine’s “Best Inventions,” underscoring its clinical and social impact in modernizing an overlooked area of women’s healthcare, and has received media coverage nationally, reflecting growing momentum behind its mission. In the Los Angeles region, ASPIVIX partnered with Tia clinics (backed by Cedars-Sinai) to offer Carevix across all 11 national locations, expanding access to more compassionate gynecological care. With a commitment to evidence-based innovation, patient-centered design, and health equity, ASPIVIX is not only disrupting outdated tools, it is creating a more modern, respectful future for women’s health globally.
